DeuteRx, LLC was spun-out from and funded by former shareholders of Deuteria Pharmaceuticals, Inc. in December 2012. The success of both companies is based on 'Deuterium-Enabled Chiral Switching' (DECS), a revolutionary strategy to improve the properties of racemic small molecule marketed drugs and drug candidates. Deuteria was sold to a major biopharmaceutical company in December 2012, <2 years after incorporation.
DeuteRx has pioneered a novel approach to the successful and profitable strategy of ‘chiral switching’. Today, numerous drugs are still developed and marketed with racemic active ingredients because the enantiomers are chemically unstable and rapidly interconvert in vivo. Representative marketed drugs include Actos®, Aricept®, Contrave®, and Revlimid®. Replacing the exchangable hydrogen at the chiral center with deuterium can enable stabilization and development of the single, preferred enantiomer to create an improved NCE with new composition of matter patent protection.